PSC Partners and PSC Partners Canada, both patient-led non-profit organizations supporting education and research in primary sclerosing cholangitis (PSC), announced today the enrollment of the first patient into the WIND-PSC study. PSC is a rare.
Mirum Pharmaceuticals (MIRM) Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum's LIVMARLI streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
- Results demonstrate 70% risk reduction for long-term clinical outcomes in patients with Alagille syndrome treated with LIVMARLI
- Data are the first to demonstrate a six-year transplant-free.
Mirum Pharmaceuticals, Inc. today announced that Hepatology published an analysis demonstrating a statistically significant improvement in six-year event-free and transplant-free survival in patients with Alagille syndrome (ALGS) treated with.
The company once described the Duwamish, one of the country’s most contaminated waterways, as “a natural collector” for its wastes. The Port of Seattle and Boeing accuse each other of failing to pay their fair shares for the cleanup.